Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tazemetostat: EZH2 Inhibitor
Rachael Straining, William Eighmy
Journal of the Advanced Practitioner in Oncology (2022) Vol. 13, Iss. 2, pp. 158-163
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications
Tong Xiao, Juyeun Lee, Timothy D. Gauntner, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 338-355
Closed Access | Times Cited: 23
The Epigenetic Hallmarks of Cancer
Manel Esteller, Mark A. Dawson, Cigall Kadoch, et al.
Cancer Discovery (2024) Vol. 14, Iss. 10, pp. 1783-1809
Closed Access | Times Cited: 20
Epigenetic drugs in cancer therapy
Amila Suraweera, Kenneth J. O’Byrne, Derek J. Richard
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 1
Open Access | Times Cited: 2
SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities
Garrett W. Cooper, Andrew L. Hong
Cancers (2022) Vol. 14, Iss. 15, pp. 3645-3645
Open Access | Times Cited: 46
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities
Álvaro Andrades, Paola Peinado, Juan Carlos Álvarez-Pérez, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 36
Calcium signalling pathways in prostate cancer initiation and progression
Roberto Silvestri, Vanessa Nicolì, Priyadarsini Gangadharannambiar, et al.
Nature Reviews Urology (2023) Vol. 20, Iss. 9, pp. 524-543
Closed Access | Times Cited: 27
Biology of GD2 ganglioside: implications for cancer immunotherapy
Pierre Machy, Erwan Mortier, Stéphane Birklé
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 27
Exosomal RNAs and EZH2: unraveling the molecular dialogue driving tumor progression
Ahmed Hussein Zwamel, Adnan Ahmad, Farag M. A. Altalbawy, et al.
Medical Oncology (2025) Vol. 42, Iss. 4
Closed Access | Times Cited: 1
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets
F Bertuccio, Simone Montini, Maria Antonietta Fusco, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1160-1160
Open Access | Times Cited: 1
Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells
Shahang Luo, Guanghui Yang, Peng Ye, et al.
Biomolecules (2022) Vol. 12, Iss. 6, pp. 850-850
Open Access | Times Cited: 36
Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas
Jiaxin Liang, Deyang Yu, Chi Luo, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Chordoma: A Comprehensive Systematic Review of Clinical Trials
Sonja Chen, Ruben Ulloa, Justin M. Soffer, et al.
Cancers (2023) Vol. 15, Iss. 24, pp. 5800-5800
Open Access | Times Cited: 13
Inhibition of the histone methyltransferase EZH2 induces vascular stiffness
Jaime Ibarrola, Rachel R. Xiang, Zhe Sun, et al.
Clinical Science (2024) Vol. 138, Iss. 5, pp. 251-268
Open Access | Times Cited: 5
Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features
Axel Künstner, Julian Schwarting, Hanno M. Witte, et al.
Leukemia (2024) Vol. 38, Iss. 5, pp. 1086-1098
Open Access | Times Cited: 4
Targeting EZH1/2: tackling epigenetic resistance advances cancer therapy
Ram Abou Zaki, Assam El‐Osta
MedComm (2025) Vol. 6, Iss. 1
Closed Access
The Gender-Biased Differential Effect of KDM6A Mutation on Immune Therapy in Urothelial Carcinoma: A Public Database Study
Yohei Sekino, Hikaru Nakahara, Kenichiro Ikeda, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 356-356
Open Access
Safety profile of EZH2 inhibitors for cancer: a systematic review and meta-analysis
Zhou Zhao, Xiufeng Chen, Hua‐Yang Pang, et al.
PeerJ (2025) Vol. 13, pp. e18871-e18871
Open Access
Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies
Wooli Bae, Eun A., Myon‐Hee Lee
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
An updated patent review of EZH2 inhibitors (2024 – present)
Guoquan Wan, Siying Li, Qiang Tang, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Integrator complex subunit 12 knockout overcomes a transcriptional block to HIV latency reversal
Carley N Gray, Manickam Ashokkumar, Derek H. Janssens, et al.
(2025)
Open Access
Integrator complex subunit 12 knockout overcomes a transcriptional block to HIV latency reversal
Carley N Gray, Manickam Ashokkumar, Derek H. Janssens, et al.
eLife (2025) Vol. 13
Open Access
Dual targeting of EZH2 and PD-L1 in Burkitt’s lymphoma enhances immune activation and induces apoptotic pathway
Yurim Jeong, Hyewon Jang, Se Been Kim, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Epigenetic Regulation of Human Vascular Calcification
Lova Prasadareddy Kajuluri, Ying Guo, Sujin Lee, et al.
Genes (2025) Vol. 16, Iss. 5, pp. 506-506
Open Access
Epigenetics: Applications in Cancer Therapeutics
S. Saravana Babu, Himansu Bhusan Samal, Marina Ramzy Mourid, et al.
(2025), pp. 237-263
Closed Access
A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma
Eimear Lagan, Dáire Gannon, Ademar Jesus Silva, et al.
Molecular Cell (2025)
Open Access
Page 1 - Next Page

Scroll to top